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Abstract
Background: The Triplex cell vaccine is a cancer cellular vaccine that can prevent almost completely the
mammary tumor onset in HER-2/neu transgenic mice. In a translational perspective, the activity of the Triplex
vaccine was also investigated against lung metastases showing that the vaccine is an effective treatment also for
the cure of metastases. A future human application of the Triplex vaccine should take into account several aspects
of biological behavior of the involved entities to improve the efficacy of therapeutic treatment and to try to
predict, for example, the outcomes of longer experiments in order to move faster towards clinical phase I trials. To
help to address this problem, MetastaSim, a hybrid Agent Based - ODE model for the simulation of the vaccine-
elicited immune system response against lung metastases in mice is presented. The model is used as in silico wet-
lab. As a first application MetastaSim is used to find protocols capable of maximizing the total number of
prevented metastases, minimizing the number of vaccine administrations.
Results: The model shows that it is possible to obtain “in silico” a 45% reduction in the number of vaccinations.
The analysis of the results further suggests that any optimal protocol for preventing lung metastases formation
should be composed by an initial massive vaccine dosage followed by few vaccine recalls.
Conclusions: Such a reduction may represent an important result from the point of view of translational medicine
to humans, since a downsizing of the number of vaccinations is usually advisable in order to minimize undesirable
effects. The suggested vaccination strategy also represents a notable outcome. Even if this strategy is commonly
used for many infectious diseases such as tetanus and hepatitis-B, it can be in fact considered as a relevant result
in the field of cancer-vaccines immunotherapy. These results can be then used and verified in future “in vivo”
experiments, and their outcome can be used to further improve and refine the model.
Background
The metastatic process is an extraordinary complex pro-
cess. In order to colonize a secondary site and to
become metastases cancer cells must complete a
sequential chain of steps which include the detachment
from the primary tumor, the invasion through surround-
ing tissues and basement membranes, the survival in the
circulation, lymphatics or peritoneal space and the
settlement in a distant target organ. In spite of this
intrinsic inefficiency, metastases represent one of the
major concerns in the clinical management of cancer.
The majority of cancer mortality is associated with this
disseminated disease rather than the primary tumor [1].
In most cases cancer patients with localized primary
tumors have significantly better prognoses than those
with disseminated tumors. Recent evidence shows that
metastases can be an early event [2] and that 60% to
70% of patients have already initiated the metastatic
process by the time of diagnosis. Even patients that have
no evidence of tumor dissemination at diagnosis are at
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risk from metastatic disease. Approximately one-third of
women who are sentinel lymph node negative at the
time of surgical resection of the primary breast tumor
will develop clinically detectable secondary tumors [3].
Transgenic mice are preclinical models which develop
autochthonous tumors and are interesting for cancer
preventive studies since they reproduce the natural evo-
lution of tumors. HER-2/neu transgenic mice are likely
the most extensively studied models for the evaluation
of approaches against mammary carcinomas that spon-
taneously develop over the course of several months.
One of these mice systems is represented by BALB-
neuT female mice, which start to develop after birth
cells hyper-expressing HER-2/neu gene product (p185)
in mammary glands. These cells give rise to multiple
microscopic lesions identifiable as atypical hyperplasia,
which progress to carcinomas in situ, becoming macro-
scopic lesions detectable at around 4-5 months of age.
One of the most effective vaccines to prevent the
onset of mammary tumors was set up in BALB-neuT
female mice. This vaccine, referred to as Triplex [4,5],
was obtained from a mammary carcinoma of a
FVBneuN #202 (H-2q) mouse, transgenic for the rat
protooncogene c-neu, and combines three different sti-
muli:
• The p185neu antigen, product of the rat HER-2/
neu gene;
• H-2q MHC molecules (allogeneic for H-2 d BALB-
neuT mice);
• Interleukin-12 (the cells are engineered with the
genes coding for murine IL-12).
The Triplex vaccine demonstrated an ability to pre-
vent almost completely neu-driven mammary carcino-
genesis [4,5]. In order to predict the best vaccination
protocol a computational model, hereafter referred as
SimTriplex model [6], has been successfully used in
conjunction with Genetic Algorithms [7]. In a transla-
tional perspective, the therapeutic activity of the Triplex
vaccine was evaluated in BALB-neuT mice against dif-
ferent stages of mammary carcinoma progression. The
study of therapeutic activity of the Triplex vaccine
showed that the vaccine loses progressively its efficacy
with the advancement of tumor progression in BALB-
neuT mice with little or no efficacy at all against incipi-
ent mammary carcinomas. On the other hand the
Triplex vaccine proved to be an effective treatment
against induced lung metastases [8]. Lung metastases
were induced in BALB-neuT mice by intravenous injec-
tion of syngeneic mammary carcinoma cells.
The administration of the vaccine started one day
after the intravenous injection of the metastatic cells
and it is repeated twice weekly up to the end of the
experiment (day 32), with lower but good prevention
rates when the same cycle is started 7 days after the
induction of the metastases (Triplex+7 protocol). The
immunological responses in the immunoprevention and
therapeutic experiments overlap only partially. A major
goal of biologists is to better understand the biological
behavior to improve the efficacy of the therapeutic treat-
ment and to try to predict, for example, the outcomes of
longer experiments in order to move faster towards clin-
ical phase I trials. Following previous experiences [9,10]
we then developed a new computational model named
MetastaSim to be used as an in silico virtual lab can
help answering these questions. The model was briey
introduced and presented as work-in-progress in [11].
The MetastaSim model can be seen as an agent-based
(ABM) or automata-like model, and it has been inspired
by the SimTriplex model. MetastaSim has in common
with SimTriplex the same modeling framework and
some of the biological mechanisms shared by the in vivo
experiments they model. However it has some impor-
tant differences.
The first differences are determined by the biological,
spatial and time-length differences entitled with the two
in vivo experiments. The immunoprevention experiment
lasts for 1 year whereas the therapeutic experiment lasts
for 1 month. SimTriplex simulates only a small fraction
of a mammary gland (1 mm3) whereas MetastaSim
reproduces the frontal ventral surface of the left lung of
a mouse, for an estimated volume which is 64 times big-
ger than those simulated by SimTriplex. The biological
behavior is also different. Cancer prevention is primarily
driven by antibodies. Interferon-g (IFN-g) is the one of
the major mediators both in cancer prevention and in
the metastasis therapy whereas anti-HER-2/neu antibo-
dies, which are key effectors of the Triplex preventive
ability, seem devoid of significant therapeutic activity.
Other vaccine-induced mechanisms playing a causal role
in the therapeutic experiment are represented by T-
helper activities at the systemic level and macrophages
infiltration in the tumor cell nests.
Apart from the aforecited physical and biological dif-
ferences, MetastaSim introduces some important
advances in respect to its predecessor. The most impor-
tant improvement the model presents consists in a com-
plete revision of the cancer growth kinetics. The model
is now able to simulate multiple different metastatic
nodules, each one with its own growth rate, more accu-
rately. To reproduce the growth in time of nodules, the
Gompertz growth law is now used in its differential
form, making the model an ABM - ODE hybrid one.
The growth rates are randomly generated in such a way
that the in silico nodule measurements resemble the
experimental measurements coming from the in vivo
experiment. Moreover a first simplified chemotaxis and
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some of the effects of the immunosuppression induced
by cancer cells have been introduced into the model as
well, in order to make the model more consistent with
the last immunological advances. After a tuning phase,
necessary to determinate the free parameters, the model
has been validated against existing in vivo experiments.
Then its first application has been to find a protocol
capable to assure against lung metastases the same pro-
tection entitled with the use of the Triplex+1 protocol.
One of the major concern of the biologists is in fact to
understand wether it is possible to gain a similar protec-
tion of the Triplex+1 protocol with less injections. Wet
biology requirements (i.e., the time required for the pre-
paration of the vaccine) as well as safeness for the mice
(i.e., the need to avoid undesirable effects) entitle that
no more than two vaccinations per week (in pre-estab-
lished days) can be done. This means that for the length
of the “in vivo” experiment (32 days) it is possible to
administer the vaccine only in 9 days. It turns out that
the Triplex+1 protocol, which already counts 9 injec-
tions, is the most intensive one because it already uses
all the available days to vaccinate. Shorter protocols
should be therefore obtained by removing some injec-
tions from Triplex+1 protocol.
Methods
The in vivo experiment
In the immunoprevention experiment, BALB-neuT mice
that have reached 6 weeks of age are exposed to a twice
weekly intraperitoneal vaccination cycle followed by two
weeks of rest (Chronic protocol) for one year. At the
end of the experiment the number of detectable lesions
is taken as the final outcome. In the therapeutic experi-
ment, instead of waiting for breast cancer to develop
into its later stages (that give rise to lung metastases),
metastases are induced by the injection of metastatic
cells. Mice in late tumor stages present various pro-
blems, such as immune system aging, the presence of a
non surgically removable primary tumor and the inabil-
ity of establishing when the metastatic process starts.
Indeed the experimental induction of metastases in
tumor-free mice clearly represents a typical scenario in
human cancer, i.e., the scenario arising after the surgical
removal of the primary tumor.
The therapeutic experiment lasts for 32 days. TuBo
mammary carcinoma neu cells (referred to as Neu/H-2)
are used to induce experimental metastases in syngeneic
BALBneuT mice. At day 0 all mice receive an intrave-
nous injection of 2.5·104 metastatic TuBo cells.
This experiment counts three different mice sets: the
untreated or control set, “set I”, where a protocol com-
posed by a “twice a week” vaccination cycle is started at
day 1 and repeated up to the end of the experiment
(Triplex+1 protocol), and “set II”, where the same cycle
is started at day 7 and repeated up to the end of the
experiment (Triplex+7 protocol).
Mice from the control set developed ≈ 200 metastatic
nodules, whereas mice from set I and II shown a reduc-
tion > 99% and ≈ 87% of early lung metastasis formation
respectively. Moreover, the structure of metastatic
lesions was frequently cribriform and less compact than
in the controls.
The three stimuli of the triplex vaccine stimulate the
immune system responses in many ways. The IL-12
enhances antigen presentation, helper T cell (TH) acti-
vation and secretion of interferon-g (IFN-g) by natural
killer (NK) and TH cells. IFN-g also has a cytostatic
activity on cancer cells (CC) and stimulates granulocytes
and macrophages (MP) in infiltrating tumor cell nests in
the lungs. TH cells have a major role at the systemic
level releasing various cytokines such as interleukin-2
(IL-2) which enhances cytotoxic T cells (TC) activities
and B cells antibodies (Ab) release. The allogeneic MHC
favors the recognition by antigen presenting cells
(macrophages, B and dendritic cells (DC)), as well as
cytotoxic T cells.
General description of the MetastaSim computational
model
The MetastaSim model uses an agent based approach to
simulate the main features of the immune system. It
takes inspiration from the SimTriplex model developed
by Pappalardo et. al. [6]. Both the innate and adaptive
immune responses are part of the model. In particular
the core of the adaptive immune response is repre-
sented, and cellular and humoral responses as well as
the presence of antigens in the host organism are
implemented.
The space is discrete. MetastaSim uses an hexagonal
lattice instead of the more familiar square (checker-
board) lattice. This is because the neighbors of a site in
a square lattice are of two different types, edges and cor-
ners. To have only neighbors of one type we choose the
hexagonal lattice where each site has six identical neigh-
bors. The lattice represents the frontal ventral surface of
the left lung of mice and it has periodic boundary con-
ditions. The model does not include the presence of
lymph nodes. However all the relevant entities and pro-
cesses that occur in lymph nodes are represented.
Perelson and Oster (1979) [12] proposed a simple
quantitative model to understand how large the immune
repertoire should be. This model is based on the notion
of shape space. In order for a receptor and the molecule
that it binds, a ligand, to approach each other over an
appreciable portion of their surfaces, there must be
extensive regions of complementarity. The constellation
of features important in determining binding among
molecules is called the generalized shape of a molecule.
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One of the key aspects of the model is represented by
the use of bit-strings to model receptors. Bit-strings are
excellent candidates to describe the concept of shape
space. This fundamental modeling abstraction ignores
nearly all of the physical details that determine recep-
tor/ligand interactions. However, by adopting character
strings, many binding events can be simulated quickly,
making it feasible to study large-scale properties of the
immune system [13].
Although character strings are unphysical, they can
produce surprisingly accurate models when bench-
marked to experiment [14], suggesting that the abstrac-
tion captures important features of receptor/ligand
binding.
The time-step for the simulation is Δt = 8 hours, since
no other biologically relevant processes for the in vivo
experiment can be observed in shorter times. At any
time step the interaction and the diffusion processes
hold.
During the interaction process the concept of physical
proximity is modeled through the concept of lattice-site:
only entities that lie in the same lattice-site can stochas-
tically interact with each others in the same site, so that
there is no correlation between entities residing on dif-
ferent sites at a fixed time.
After the interaction phase, entities can move from a
lattice-site to another one in the neighborhood. Major
bone marrow and thymus functions, like the positive
and negative selection of immature T lymphocytes
before they get into the lymphatic system, are also
represented.
Cells and molecules
The model includes the major cell types needed to
represent the immune responses elicited by the vaccine.
The main involved types of cells and molecules repre-
sented are dendritic cells (DC), macrophages (M), nat-
ural killer cells (NK), vaccine cells (VC), cancer cells
(CC), b lymphocytes (B), cytotoxic lymphocytes (TC), t-
helper lymphocytes (TH), antibodies (Ab), antigens (Ag),
immunocomplexes (IC), interleukin-2 (IL-2), interleu-
kin-12 (IL-12) and interferon-g (IFN-g).
More than one entity can be present at the same time
in a lattice site. Cells are followed individually through-
out the course of an experimental run because their
internal states and receptors follow their own, individual
life histories.
All cells have MHC class I receptors. APCs (macro-
phages and dendritic cells) and B cells also have MHC
class II receptors. Macrophages and dendritic cells have
receptors (i.e., Toll-like receptors) used for recognizing
antigens aspecifically. These aspecific receptors are not
represented explicitly. B cells, TH cells and Tc cells are
endowed with receptors used for binding specific anti-
gens. The B cell receptor (BCR) binds antigen which it
can then ingest and endocytose. The T cell receptors
(TCR) only bind antigen in MHC/peptide complexes.
When B cells become plasma cells, they have no specific
receptor, however they produce antibodies with the
same receptor shape as the B cell from which they are
descended.
With respect to the internal states, it is possible to
describe the cells as finite state machines. In particular,
they can take a state from a certain set of suitable states
and their dynamics are realized by means of state-
changes. A state change takes place when a cell interacts
with another cell or with a molecule. Molecules are
represented in the model as site-specific concentrations,
since they have only a fixed set of properties that does
not change throughout the simulation. These molecules
include antigens, antibodies and various cytokines.
Antigens can be schematized as molecular structures
containing essentially two different portions: epitopes
and peptides. Epitopes represent the external part of an
antigen that is recognized by, for example, a B-cell
receptor whereas peptides represent the internal portion
of the antigen that can be bound by an MHC molecule,
expressed on a cell surface, and recognized by the
appropriate T cell.
Epitopes and peptides are represented in the model by
two distinct arrays of binary strings. The minimum anti-
gen is constituted by just two strings, one for the epi-
tope and one for the peptide.
Antibodies are represented in the same way as anti-
gens, i.e., bit-strings. Antibodies contain both foreign
(arising from the variable regions) and self (arising from
the constant regions) peptides. Lastly, they contain the
Fc portion, an epitope identical for all antibodies that is
not explicitly represented since it is the same for all of
them.
The model also represents some important cytokines
which are represented by enumerating their concentra-
tion (number of molecules) for each lattice-site.
Entities interactions
Every interaction is a complex process that usually
involves entities state change. It is possible to distin-
guish between specific and aspecific interactions. Speci-
fic interactions require the presence of specialized
receptors for the recognition phase, such as those of B
and T lymphocytes. For these kinds of interactions the
probability of recognition is defined as a function of the
Hamming distance between the receptors, and the affi-
nity of the interaction can be enhanced by adjuvants.
Aspecific interactions entail the use of aspecific recep-
tors, so the recognition phase is not represented expli-
citly. When two entities that may interact, occur at the
same lattice site, they interact probabilistically.
The network of interactions the model uses is repre-
sented in figure 1.
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Vaccine cells (VC) can be directly recognized by TC
cells and NK cells. The Allogenic MHC-I molecules
favor the interaction with TC cells that proceed to kill
them. NK cells can recognize VCs bounded by antibo-
dies. Killed VCs release the tumor associated antigen
(TAA) and IL-2.
The TAA can be captured by DC, MP and B cells that
proceed to internalize the antigen and to present it with
the MHC-II to TH cells. DC cells can also cross-present
the antigen in conjunction with MHC-I to TC cells.
TH cells are activated by the interaction and proceed
to release IL-2. B cells are also stimulated by interaction
Figure 1 The interactions network implemented in MetastaSim. The generalized interactions scheme. Some minor entities and interactions
are omitted to improve readability.
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with TH cells to differentiate into Plasma cells (P) or,
eventually, into Memory B cells. P cells release antibo-
dies (Ab) which can bind both Vaccine and Cancer cells
favoring NK killing activity. NK cells can also kill CCs
that under-express the MHC complex.
Abs can also bind the antigen giving rise to Immuno-
complexes (IC) that are then phagocyted by MPs. In
addition they can activate the complement system with
lysis of CCs as result. IL-2 promotes TC and TH activ-
ities, and B differentiation.
IL-12 promotes NK activities and TC activation.
Moreover it stimulates TH cells and (to a lesser extent)
NK cells to release IFN-g. IFN-g has cytostatic effects on
CCs and stimulates both the killing of CCs and the
release of IL-12 by MPs.
It is easily understandable that the complex network
of interactions presented here has many cycles in it, i.e.,
TH ↔ IL-2. These cycles usually involve non-linearities
that the model is however able to handle without any
problem.
How simulation proceeds
The first step of the simulation consists of initialization.
After cells generation and thymic selection processes,
the grid is populated by randomly placing the various
cell types in the lattice.
Interactions take place between entities that occupy
the same site, and all entities have the opportunity to
interact at every time-step. Ideally all the interactions
should be executed at the same time. This is obviously
not possible. Since the interactions dynamics of a lat-
tice-site is not influenced by those of the other sites, the
only problem is to decide how to manage interactions
that occur at the same site.
At any time-step and for every lattice-site an interac-
tion scheme is generated by choosing a random order
for the interaction rules, with the interactions executed
as defined by interaction scheme. Given a specific inter-
action A ↔ B between entities of type A and B, every
entity of type A is compared with all the entities of type
B in the same site until a successful interaction occurs.
Then, the next entity of type A is taken into considera-
tion and it is compared again with all the entities of
type B in the same lattice site. When all the entities
have had their chance to interact, the next interaction
rule in the interaction scheme is examined.
It is here that the concentration dependence of the
model arises. For example, an APC may only have an anti-
gen binding strength of 0.001, but if there are 100 antigens
in the site the APC will have an opportunity to bind each
of them. The resulting probability that the APC will actu-
ally bind an antigen will be approximately 0.1.
The next step after the interaction phase is repre-
sented by entity propagation. All the entities have a
chance to move from the lattice site where they are to
another one in the neighborhood. All the lattice sites
have normally the same probability of being chosen as
new positions. However, in a first attempt to mimic che-
motaxis, higher probabilities are given to sites contain-
ing a congruous number of cancer cells. This
“simplified-chemotaxis” is only active for some entities
such as, for example, TCs and MPs.
Other minor processes related to non interaction-dri-
ven dynamics such as aging and natural death, differen-
tiation and mutation, are then executed. Time step
interactions will proceed up to a preselected final time.
Modeling of the metastatic growth pattern using the
Gompertz growth law
The untreated mice scenario represents the development
of the metastatic burden in untreated mice. It is the
most computationally expensive scenario since, due to
the lack of vaccination, the number of cancer cells grow
enormously (≈ 107 different cells in each simulation)
resulting in a memory intensive application. For model-
ing the development of the metastatic burden two
strictly connected problems arose:
• How to obtain in the model nodule sizes whose
distribution is somewhat similar to the in vivo
experiment.
• How to represent the growth pattern of the
nodules during the simulation.
In the in vivo experiment, keeping track of the tem-
poral evolution of nodules sizes is not achievable,
because to measure the nodules mice have to be killed
and they cannot obviously continue in the experiment.
Thus, to represent the temporal growth kinetics of
nodules, some assumptions were made. Biologists
firstly assumed that every metastatic nodule has origi-
nated from an individual “progenitor” cancer cell. This
means that approximately only one cancer cell in 100
passes through lung capillary vessels and settles into
the lungs showing, indeed, how inefficient the meta-
static process is.
We note here that, since the positioning process is not
relevant for the experiment, the simulation starts with
cancer cells already settled in the lungs. At the begin-
ning of the simulation n “progenitor” cancer cells are
then randomly positioned on the lattice.
Preliminary statistical analyses (Chi-Square and
Anderson-Darling test) on the nodule diameters coming
from the left lung of 8 mice under the null-hypothesis
of normality or log-normality [15] showed that neither
of the two distributions approaches in vivo data.
Observing in vivo results and taking into account the
“one cell-one nodule” hypothesis, we deduced that dis-
tinct groups of cells originating from the same progeni-
tor represent different populations, each one with its
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own growth rate. Many factors, and in particular a non-
homogeneous distribution of nutrients in lungs, can
determine these different growth rates for the nodules.
The reaction-diffusion model for the growth of tumors
by Ferreira et. al. showed that using nutrients [16] the
growth in time of the cancer approached to a Gompert-
zian growth. Results by Kendall [15] showed indeed that
Gompertzian growth hypothesis fits well with experi-
mental data coming from distributions of human
metastases.
Since the distribution of nutrients in the lungs is
neither homogeneous nor known, we therefore sup-
posed that nutrients would lead to Gompertzian growths
in time and hence we reproduced the growth kinetics of
the nodules using the Gompertz growth law [17].
The Gompertz law, introduced in 1825 by Benjamin
Gompertz, is a sigmoid function suitable for describing
populations growths. The law uses two factors: a growth
factor that decreases in time and a constant mortality
factor. Thanks to the growth factor deceleration, the
dimension of the population tends asymptotically to a
certain threshold (the carrying capacity). This model is
particularly suitable for the following phenomena:
• Mobile phone uptake, where costs were initially
high (so uptake was slow), followed by a period of
rapid growth, followed by a slowing of uptake as
saturation was reached.
• Population in a confined space, as birth rates first
increase and then slow as resource limits are
reached.
• Modeling of the growth of tumors, where the
approaching of the asymptote usually represents the
presence of anti-angiogenic growth factors.
Let x(t) be the number of cancer cells at time t, the
differential form of the law is given by:
dx t
dt
ax t bx t x t
( )
( ) ( ) ln ( )= − ⋅ ( )
where a represents the intrinsic grow factor of the
tumor, usually connected to the nutrient availability,
and b is the mortality factor. Having as an initial condi-
tion x(0) = x0, the solution of the equation is:
x t e
a
b e
a
b x e
a
b e
x e
e bt
bt
bt
( ) ( )
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= = −
− −
⎛
⎝
⎜
⎜
⎞
⎠
⎟
⎟ −
−
−0
0 1
Other formulations use the following form:
x t x e
a
b e bt( ) ( )= − −0 1
As previously stated, biologists supposed for the pro-
blem we are dealing with that every metastatic nodule
originates from a single “progenitor” cancer cell (x0 =
1). For this reason the coefficient x0 can be removed.
The model can therefore be simplified to:
x t e
a
b e bt( ) ( )= − −1
To model in silico the same nodule sizes distributions
of the in vivo experiment we then decided to use the
inverse transform sampling method [18]. Starting from a
random variable u uniformly distributed in 0[1], the
method allows us to obtain a random variable X distrib-
uted according to some desired experimental data.
The algorithm of the method is as follows:
• Build the cumulative distribution function F(x)
using experimental data;
• Consider (y) = F-1(x);
• Generate a random value u uniformly distributed
in the range [0, 1];
• Return r = (u) distributed according to experi-
mental data.
Supposing that we want to simulate k metastatic
nodules, we can now generate k random nodule measures
distributed according to experimental data. nodules have
a spherical form, we can estimate the number of cells x
contained in a nodule with a diameter r as follows:
x
r
d
=
⎛
⎝⎜
⎞
⎠⎟
⎛
⎝⎜
⎞
⎠⎟
2
3
2
3
where d represents the mean diameter of a TuBo can-
cer cell.
Starting from x, we have then to find a and b in a
such way that, using the Gompertz law, the diameter of
the nodule at the end of the simulation should be near
to the expected value.
The knowledge of x is not enough for our aim since we
have two unknown variables and just one equation, and
this leads to an infinite set of possibilities. For this reason
Biologists supposed that, at the end of the experiment,
the nodules reached only 50% of the maximum diameter
they can have before approaching close to their carrying
capacity. Applying the logarithm function to both mem-
bers, the previous equation translates into:
ln ( ) ( )x t
a
b
e bt= − −1
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Since each time-step is 8 hours and the experiment
lasts for 32 days, we need t′ = 96 time-steps to complete
the simulation.
As previously stated, the law also tends asymptotically
to its carrying capacity. If we call x* the number of cells
of a nodule at its carrying capacity, the following limit
holds:
lim
( ) *
t
a
b
e
e x
bt
→∞
− −
=
1
Moreover, since the term e-bt ® 0 for t ® ∞, we can
suppose that for t ≫ t’ the following statement holds:
a
b
x≈ ∗ln
Proceeding with substitution we have:
ln
ln
( )
x
x
e bt∗ = −
− ′1
and finally:
b
x
x
t
a
x b
e bt
= −
− ∗
⎛
⎝
⎜
⎞
⎠
⎟
′
= ⋅
− − ′
⎡
⎣
⎢
⎤
⎦
⎥
ln
ln
ln
ln( )
1
1
The obtained k parameters (ak, bk) are associated at
time-step 0 to the k randomly positioned cancer cells.
At any time-step the Gompertz law is used to compute
the duplication rates that cancer cells belonging to the
specific nodule should have.
In particular, starting from the differential form of the
law
dx j t
dt
a x t b x t x tj j j
( )
( ) ( ) ln ( )= − ⋅ ( )
we discretize the equation with the forward Euler
method obtaining
x x t x a b xj
t
j
t
j
t
j j j
t+ − = Δ − ⋅1 ( ( ln( ))).
Having discrete time-steps, we can suppose Δt = 1. If
we divide all the members by x j
t we have:
w
x j
t x j
t
x j
t
a b xj j j j
t=
+ −
= − ⋅
1
( ln( ))
Where the index j identifies the nodule (or the popu-
lation) j, j Î 1 ... k, wj represents the duplication ratio
for all the cells belonging to the nodule j and x jt+1 and
x j
t are the number of cancer cells of the population j at
time-step t + 1 and t, respectively.
Tuning and validation of the model
Prior to use the model as in silico wet lab, it has to be
tuned and validated against existing in vivo experi-
ments. All models have a certain number of para-
meters which can be freely chosen in a certain range.
Biological knowledge has been used to guess reason-
able initial ranges. Then fine tuning has been done in
such a way that in silico experiments fit in vivo ones.
For the reproduction of the metastatic growth pattern
it has been possible to utilize experimental data on the
distribution of nodules in sizes (diameters) coming
from untreated mice. Thus for all scenarios the num-
ber of nodules at the end of the “in vivo” experiment
has been used.
MetastaSim describes the metastatic growth pattern
and immune response elicited by the vaccine against it
for a single mouse. Parameters tuning must entitle as
result that the simulator, applied to mice with different
vaccine protocols, gives as result a reliable representa-
tion of the “in vivo” experiment. Note that immune sys-
tem behavior should agree with biological knowledge.
For this reason major entities mean plots were also sub-
mitted to biologists and checked for their approval.
The tuning procedure was done using few, randomly
selected, individual mice. Parameters are varied under a
certain range and then simulations are executed on the
sample set. Obtained results are then checked. When a
reasonable tuning has been found, “in silico” validation
of the model has been done using the following experi-
mental procedure:
• Generate a large population of individual mice,
each one with a different random seed which will
determine different probabilistic chain events.
• Randomly extract from the population two statisti-
cal samples of 100 individual mice to perform
numerical experiments.
• Simulate all the scenarios on the two sample sets.
Note here that none of the mice used during the tun-
ing procedure has been used also for validation.
The treated scenarios
The tests have been executed on two different mice
samples, each one composed by 100 virtual mice. For
every mice set the untreated mice as well as the
two treated mice scenarios (vaccination started at day
Pennisi et al. BMC Bioinformatics 2010, 11(Suppl 7):S13
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1 with Triplex+1 protocol and at day 7 with Triplex+7
protocol respectively) have been reproduced. Since
MetastaSim simulates the frontal ventral surface of the
left lung of mice, the initial number of metastases
already settled in the lungs at the beginning of the
simulation has been estimated using experimental data
and has been set to 35. The number metastases has
been taken as the outcome of the simulations for all
the scenarios.
Median values relative to the two treated mice scenar-
ios have been then compared against those coming from
the untreated mice scenario and the percentages of pre-
vented metastases (in respect to the untreated scenario)
have been estimated, thus following the same procedure
used “in vivo” [8].
Evaluation of “in-silico” predicted protocols
The MetastaSim simulator usually requires no more
than 5 minutes to test a protocol on a single mouse.
An upper bound for the required total CPU time is ≈
100·512·5 ≈ 177.8 days on a single cpu computer. It is
possible to overcome this time limit by running multi-
ple simulations at the same time using an HPC
infrastructure. Resources from the CINECA Italian
supercomputing center (BCX cluster) have been then
used for the purpose, launching 8 different MPI jobs
(each one requiring 128 cores) for approximately
4 hours. The total employed time has been ≈ 4000
hours, which corresponds to 167.7 days on a single
cpu computer.
In order to establish whether a protocol is better than
another, an order criterion (a fitness or rank function)
must be used. For this reason the following rank func-
tion has been used:
Let N* ⊂ R be the set which contains all the possible
values Ni described before, and let T ⊂ R be the set of
all possible number of injections Ti for each protocol i.
Each protocol i can be described as a point (Ni, Ti) in
the space (N*, T). Ideally the optimum protocol lies in
the origin (0, 0), since it is able to entitle 0 metastatic
nodules with 0 injections. Of course such a protocol
does not exist. However the best protocols will be the
ones whose distance from the origin is minimum. The
following sort criterion is then used:
r N k Ti i i= + ⋅
2
3
2( )
where k3 is a fixed constant used to properly scale T.
The goal of this exhaustive search is to find protocols
with the same protection rate as “Triplex+1” protocol
but with less injections, so protocol prevention rates
must be favored in respect to the number of injections.
For this reason k3 has been empirically set to 15.
Results and Discussion
Results
Validation of the untreated mice scenario
For the untreated mice scenario, results coming from in
silico and in vivo tests were compared using the Kolmo-
gorov-Smirnov test in its two-sample variant [19].
We tested the mean in vivo nodule sizes distribution
(coming from 8 different mice) against 8 different in
silico distributions. Nodule measurements of the in silico
distributions were estimated starting from the number
of cancer cells of each nodule and supposing spherical
form for both cells and nodules.
Using a standard significance level a = 0.05, for none
of the tests we were able to reject the null hypothesis
that the two samples are drawn from the same distribu-
tion (see table 1, P column). Moreover the maximum
distances between the two distributions (table 1, D col-
umn) are usually very limited, suggesting that the in
silico obtained nodule size distributions are in good
agreement with the in vivo ones. This result can also be
observed in figure 2, where we compare the cumulative
fraction plot of the in vivo experiment against the ones
obtained in the in silico experiments. In figure 3 we
show an example of the nodules spatial distributions
obtained in vivo and in silico.
Validation of the treated scenarios
The Kolmogorov-Smirnov test was not used for testing
the nodules distributions coming from simulations of “Tri-
plex+1” and “Triplex+7” vaccine protocols. The biggest
problem here is represented by the small number of
nodules arising in vaccinated mice. In order to execute
any statistical test, a sample set should be big enough to
be considered significative, i.e., as a valid representation of
the phenomenon. Speaking of nodules distributions when
the “in vivo” scenario has a too limited number of nodules,
if none (as in the case of mice treated with “Triplex+1”
protocol), makes nonsense.
Table 1 Results from the two-sample Kolmogorov-
Smirnov statistical test
MOUSE Reject P D
4609 No 1 0.0485
2692 No 0.491 0.1451
735 No 0.997 0.0700
1824 No 0.877 0.1027
5155 No 0.113 0.2087
7659 No 0.990 0.0770
6105 No 0.212 0.1843
3378 No 0.435 0.1515
The first column represents the random seed of a given mouse. The second
column reports the result of the test (whether the null hypothesis is rejected),
the third column (P) shows the value returned by the test (to be compared to
the significance level), and the last column (D) the maximum distance
between the two distributions (maximum norm).
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Figure 2 Cumulative fraction plots for the in vivo and in silico untreated mice distributions. Comparison of the cumulative fraction plots
for the in vivo and the in silico distributions for the untreated mouse case. The “X” axis represents the (estimated for the in silico experiments)
diameter of metastatic nodules expressed in ocular micrometer notches. The solid line represents the cumulative fraction plot for the in vivo
experiment; the dashed line represents the cumulative fraction plot obtained for the in silico experiments.
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To validate results coming from the “in silico” experi-
ment against the “in vivo” results presented in [8],
MetastaSim has been executed on two different mice
sample sets simulating all the three scenarios: untreated
mice, mice treated with the Triplex+1 protocol and
mice treated with the Triplex+7 protocol. Then the
number of arising nodules has been taken as the out-
come. The median value for each experiment was con-
sidered and the percentage of prevented nodules has
been estimated and compared with the “in silico”
results. The methodology used here is similar to those
used by biologists in their experiment.
For each scenario the number visible nodules for each
mouse has been taken as the outcome of the experi-
ment, then the median has been taken into account. In
the “in vivo” experiment, the untreated mice sample set
presented a median of visible nodules > 200, whereas
the mice sample set treated with a twice a week vaccina-
tion cycle started at day 1 presented a median value of 3
visible nodules, showing ≈ 99% reduction of the meta-
static burden [8]. In the “in silico” experiment, the
untreated scenario presented a median number of visible
metastases of 30 and 29 for set I and set II respectively.
An “in silico” 99% reduction of nodules would mean
that only ≈ 1 mouse out of three would have evidences
of the metastatic development. This would also entitle a
median value of 0. On the other hand such a value
could be easily mistaken to complete prevention of
metastases (i.e., 100% prevention). To provide a more
accurate estimation in the number of prevented
metastases, the mean number of metastases has been
taken also into account for this scenario.
Mice whose vaccination started at day 1 showed a
median of 0 for both the sample sets. Mean values for
sample set I and sample set II are 0.33 and 0.21 respec-
tively, denoting a perfect agreement between “in silico”
and “in vivo” prevented metastases percentages.
Mice whose vaccination started at day 7 showed a
median of 5 for both the sample sets. Comparison with
medians in untreated mice (30 and 29 for set II and set
II respectively) suggests a percentage range of 82,7% -
83,3% in the number of prevented metastases, against an
“in vivo” obtained percentage (≥ 87%). This indicates a
good agreement between “in silico” and “in vivo” pre-
vented metastases percentages even for the Triplex+7
protocol. Results are shown in table 2.
Exhaustive search for optimal vaccine schedules
The search space for the problem counts 29 = 512 pos-
sible different protocols and it is therefore very limited.
In this case it is advisable to use an exhaustive search
rather than an optimization technique, as shown in
[20,21] for the SimTriplex model, to find an optimal
protocol.
However it is important to note here that the exhaus-
tive search should not be executed on a single mouse.
We have indeed chosen to execute the exhaustive search
on 100 different mice. Results relative to the first 20
best protocols are shown in table 3.
As the outcome of the experiment the total number of
metastases ni
j has for every protocol i = 1 ... 512 and
Figure 3 Nodules distributions in in vivo and in silico experiments. Examples of nodules distributions obtained in vivo (l.s.) and in silico (r.s.).
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every mouse j = 1 ... 100 has been taken into account. The
median numbers Ni of the number of formed metastases
has been then calculated for every protocol i on ni
j .
A first analysis of the results confirmed biologists
expectations: protocols counting more early vaccine
administrations give better results than protocols with
late vaccinations. For example, using 4 administrations,
protocol 15 = 111100000 is able to elicit almost com-
plete protection with Ni, whereas protocol 480 =
000001111 turned out to be almost useless with Ni = 24.
Results also show that it is possible, using protocols 87
and 103, to achieve “in silico” (with just 5 injections) the
same protection elicited by the 9-injections protocol
“Triplex+1”. Figure 4 summarizes the mean behaviors
(computed on 100 mice) for the most important entities
in mice without treatment, using protocols “Triplex+1”,
“Triplex+7” and protocol 87 which consists of 5 injec-
tions. From figure 4 it is possible to see that the 5-injec-
tions protocol 87 is able to entitle similar immune
response as the “Triplex+1” protocol. B lymphocytes (B)
(b), cytotoxic T cells (TC) (d), T helper cells (TH) (c),
and Macrophages (MP) (e) plots show how the vaccine
is able to favor immune system responses thanks to the
earlier appearance of the antigen (Ag) and of interleukin
12 (IL-12) (g). Also interleukin 2 (IL-2) (f) appears ear-
lier and in greater quantities. The lack of the initial two
injections shows how the “chemotaxis-driven” stronger
immune response entitled with the use of protocol “Tri-
plex+7” (see in particular the cytotoxic T cells dynamics,
boosted also by the “TC activation” interaction with a
bigger number of Cancer Cells) is however unable to
effectively deal with the exponential growth of the meta-
static nodules.
Discussion
We have presented MetastaSim, a computational model
to be used as in silico wet-lab. The in silico validation
Table 2 Results from validation of the treated scenarios
Vaccination Injected Cells Median Range Estimated Prevention
“In vivo” experiment
No - > 200 134 to > 200 -
Day 1 - 3 0 - 27 ≈ 99%
Day 7 - 26 1 - 165 ≥ 87%
“In silico” 100 mice Sample I
No 35 30 23 - 34 -
Day 1 35 0 (mean 0.33) 0 - 2 ≈ 99%
Day 7 35 5 0 - 12 ≥ 83,3%
“In silico” 100 mice Sample II
No 35 29 23 - 34 -
Day 1 35 0 (mean 0.21) 0 - 2 > 99%
Day 7 35 5 1 - 11 ≈ 82,7%
Results obtained in the “in vivo” experiment and in the “in silico” experiments on mice Set I and II using the following vaccine protocols: “Untreated” (No
vaccination), “Triplex+1” (Day 1) and “Triplex+7” (Day 7). The “Injected” column represents the number of cancer cells positioned in the lattice in the “In silico”
experiments at the beginning of the simulation. The “Median” column shows the nodule medians obtained at the end of the experiments. The “Estimated
prevention” column indicates the efficacy of a protocol in vaccinated mice in respect to untreated mice, and it is computed comparing the medians obtained in
vaccinated mice against the medians obtained in untreated mice.
Table 3 Classification of best protocols found using the
exhaustive search
Protocol ID Protocol Injections Median
87 001010111 5 0
103 001100111 5 0
119 001110111 6 0
183 010110111 6 0
215 011010111 6 0
311 100110111 6 0
343 101010111 6 0
375 101110111 7 0
471 111010111 7 0
255 011111111 8 0
447 110111111 8 0
503 111110111 8 0
511 111111111 9 0
47 000101111 5 0,5
199 011000111 5 0,5
231 011100111 6 0,5
303 100101111 6 0,5
127 001111111 7 0,5
7 000000111 3 1
15 000001111 4 1
The “Protocol ID” column identifies the protocol used. The “Protocol” column
represents the protocol in binary format (i.e., 1/0 equals to administration/no
administration at the desired day). Rightmost bits represent earlier
vaccinations (at the beginning of the experiment); leftmost bits represent later
vaccinations (at the end of the experiment). The “Injections” column counts
the number of injections of the desired protocol. The “Median” column shows
the obtained median relative to the total number of nodules, and it is
determined over a set of 100 virtual mice.
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showed a good agreement with the in vivo results [8]
(tables 1 and 2), demonstrating that the model is able to
coherently reproduce the in vivo experiments. The
model has been then used to try to predict protocols
capable of assuring the same protection entitled with
the Triplex+1 protocol but with fewer injections. An
exhaustive search for any optimal protocol has been per-
formed. Results showed that it is possible to obtain in
silico a reduction of approximatively 45% in the number
of vaccinations (table 3). An important thought rises up
from analyzing the results presented in table 3. Most of
the protocols presented there share a similar vaccination
strategy which is composed by a boost of three vaccine
injections, a period of rest, and then a series of vaccine
recalls that are somewhat equally spaced. The model
suggests that any optimal protocol for preventing lung
metastases formation should be therefore composed by
an initial massive vaccine dosage followed by few vac-
cine recalls. Even if this is a well-known vaccination
strategy in immunology, since it is commonly used for
many infectious diseases such as tetanus and hepatitis-B,
it can be still considered a relevant result in the field of
Figure 4 Comparison of behaviors using 1+Triplex and Protocol 87. Mean dynamics of relevant entities in untreated (red line) and treated
mice using Triplex+1 (blue line), Triplex+7 (green line) and protocol 87 (purple line). From left to right, up to down: Cancer cells (CC) (a), B cells
(B) (b), TH cells (TH) (c), TC cells (TC) (d), macrophages (MP) (e), interleukin-2 (IL-2) (f), interleukin-12 (IL-12) (g) and interferon-g (INF-g) (h). CC, Ag,
IL-2, IL-12 and INF-g plots are presented on a logarithmic scale to improve comparison.
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cancer-vaccines immunotherapy. Another fact that
should be noted here is that protocol 7, which counts
only the initial boost of three injections, is able to entitle
a high level of protection against metastases. This
underlines the importance of the first boost of vaccina-
tions, and partially justifies the not so optimal preven-
tion rates given by protocol “Triplex+7”, which does not
include the initial boost. To deal with an exponential-
like growth of cancer cells (like a Gompertz growth
[17]), a significant vaccination should be a administered
in time, in order to train the immune system to engage
a fight against cancer cells and to kill them before their
number grows enormously. Later vaccine recalls can
indeed be useful to keep immunity at a high level in
order to readily react against escaped or dormant cancer
cells.
Conclusions
The metastatic process is extremely complex and ineffi-
cient. However, in spite of their inefficiency, metastases
are a major cause of mortality in cancer patients.
Innovative approaches, both on the therapeutic and
immunopreventive side, are nowadays the major hopes
for eradicating this appalling disease. Mathematical and
computational models to simulate and to better under-
stand “in vivo” experiments can represent a valuable
help to biologists and physicians. Nevertheless immune
system complexity requires non-conventional simulation
techniques to correctly model and simulate the immune
behavior. The MetastaSim computational model repre-
sents one of these techniques.
Using an agent-based approach, we model the
immune system at the cellular-level without excluding
important features and phenomena observed at the
molecular scale, like receptors, that are vital to mimic
important biological processes such as clonal selection.
Starting from low-level components and interactions,
the model is then able to show population behaviors at
a higher level.
The Gompertz law (in its differential form) is also
used to reproduce the growth patten in time of meta-
static nodules, making the model an ABM-ODE hybrid
model.
The model has been tuned using “in vivo” experimen-
tal data, and the results confirm that there is a good
agreement between the “in silico” and “in vivo” experi-
ment. It has been then used as an “in silico” wet-lab to
find an optimal protocol, capable of assuring almost
complete prevention of lung metastases formation with
fewer injections. Results showed that it is possible, with
a reduction of approximatively 45% in the number of
vaccine injections, to achieve the same protection
entitled by the “Triplex+1” chronic protocol. This may
represent a remarkable result since from a point of view
of translational medicine towards clinical Phase-I trials
in humans, it is usually desirable to minimize the num-
ber of vaccinations, to minimize the risk of undesirable
effects and to speed-up the entire process.
Moreover the model suggested an optimal vaccination
scheme for preventing lung metastases formation.
According to the obtained results, the vaccine strategy
should be composed by an early significant vaccine
dosage followed by few vaccine recalls in order to deal
with cancer cells’ exponential growth. Such a strategy
can be then tested and adopted instead a chronic “lin-
ear” strategy (i.e., the same equally spaced vaccination
cycles for the entire experiment), since it could allow
similar optimal results with a reduction in the number
of vaccinations.
These results can be then used and verified in future
“in vivo” experiments, and their outcome can be used to
further improve and refine the model.
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